Invited by Howard Chang—the physician-scientist who led a renowned genomics laboratory at Stanford and now serves as Senior Vice President, Global Research, and Chief Scientific Officer at Amgen—Mauritz Kop consulted with Amgen's research organization on quantum-biomedical discovery: a disciplined exchange of ideas about where quantum methods can genuinely improve the way medicines are found.
An invitation from Amgen's chief scientist
The conversation paired deep biology with quantum strategy and governance. Its anchor was the Hippocratic Quantum approach Kop published at Harvard: accelerate discovery with quantum and quantum-classical methods, but under guardrails medicine itself would prescribe—validation, privacy, security, and patient trust from the first experiment. The same translational seriousness ran through the responsible-quantum lecture and workshop Kop gave at SandboxAQ.
Six use cases, one discipline
From computational chemistry for de novo discovery and lead optimization, through protein structure and selected omics analytics, metabolism and toxicity simulation, blood-brain-barrier hypotheses validated in organoid and lab-on-a-chip systems, operational optimization, and a watchlist for quantum neural networks—every candidate use case answers to the same rule: benchmark hard against strong classical baselines from day one, and let the evidence decide which pilots earn the next dollar.
Guardrails before hype
The strategy's quiet half is security and governance: a post-quantum cryptography roadmap for long-lived patient and research data, vendor diversification across qubit modalities, trade-secret and IP protection, and standards alignment. What the exchange was about, in the end, is decision quality—smarter discovery pipelines, better-protected data, and medicines that reach patients sooner.
Meer lezen